Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20012923 | 1.00 | CFTR (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22824153 | 1.00 | CFTR (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL6205340 | 0.83 | SLC6A2 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL2608570 | 0.80 | SMN1; SMN2 (0.51) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL18513564 | 0.79 | CFTR (0.55) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1753695 | 0.79 | CFTR (0.55) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL9906896 | 0.79 | CFTR (0.55) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22454258 | 0.78 | TRPV1 (0.42) | PRMT5WDR77SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL7707812 | 0.77 | SMN1; SMN2 (0.42) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL18513674 | 0.77 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | CFTR 47/4885SLC6A2 3171/4885SLC6A4 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.